Aarti Drugs Limited (AARTIDRUGS.NS)
INR 431.7
(-0.22%)
INR 431.7
(-0.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.64 Billion INR | -7.33% |
| 2022 | 6.08 Billion INR | 12.18% |
| 2021 | 5.42 Billion INR | 54.75% |
| 2020 | 3.5 Billion INR | -9.75% |
| 2019 | 3.88 Billion INR | -23.38% |
| 2018 | 5.07 Billion INR | -7.15% |
| 2017 | 5.46 Billion INR | 13.92% |
| 2016 | 4.79 Billion INR | -0.81% |
| 2015 | 4.83 Billion INR | 7.93% |
| 2014 | 4.47 Billion INR | 18.28% |
| 2013 | 3.78 Billion INR | 18.15% |
| 2012 | 3.2 Billion INR | 7.59% |
| 2011 | 2.97 Billion INR | 11.37% |
| 2010 | 2.67 Billion INR | 41.66% |
| 2009 | 1.88 Billion INR | -1.76% |
| 2008 | 1.92 Billion INR | -11.48% |
| 2007 | 2.17 Billion INR | 9.02% |
| 2006 | 1.99 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 5.88 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 5.64 Billion INR | -7.33% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 5.64 Billion INR | 0.0% |
| 2023 Q2 | 5.89 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 6.08 Billion INR | 12.18% |
| 2022 Q4 | 6.08 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 5.85 Billion INR | 0.0% |
| 2021 Q2 | 4.7 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 5.42 Billion INR | 54.75% |
| 2021 Q4 | 5.42 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 3.5 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 3.38 Billion INR | 0.0% |
| 2020 FY | 3.5 Billion INR | -9.75% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 3.88 Billion INR | -23.38% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 4.38 Billion INR | 0.0% |
| 2019 Q4 | 3.88 Billion INR | 0.0% |
| 2018 Q2 | 5.17 Billion INR | 0.0% |
| 2018 Q4 | 5.07 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 5.07 Billion INR | -7.15% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 5.46 Billion INR | 13.92% |
| 2017 Q4 | 5.08 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 4.84 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 4.79 Billion INR | -0.81% |
| 2016 Q4 | 4.79 Billion INR | 0.0% |
| 2016 Q2 | 4.11 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 4.83 Billion INR | 7.93% |
| 2015 Q2 | 4.78 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 4.83 Billion INR | 0.0% |
| 2014 Q4 | 4.47 Billion INR | 0.0% |
| 2014 FY | 4.47 Billion INR | 18.28% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 3.95 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 3.25 Billion INR | 0.0% |
| 2013 Q4 | 3.78 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 3.78 Billion INR | 18.15% |
| 2012 FY | 3.2 Billion INR | 7.59% |
| 2012 Q4 | 3.2 Billion INR | 0.0% |
| 2012 Q2 | 1.19 Billion INR | 0.0% |
| 2011 FY | 2.97 Billion INR | 11.37% |
| 2010 FY | 2.67 Billion INR | 41.66% |
| 2009 FY | 1.88 Billion INR | -1.76% |
| 2008 FY | 1.92 Billion INR | -11.48% |
| 2007 FY | 2.17 Billion INR | 9.02% |
| 2006 FY | 1.99 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | -294.452% |
| Ind-Swift Limited | 10.13 Billion INR | 44.352% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -69.54% |
| Sakar Healthcare Limited | 793.51 Million INR | -611.101% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 91.512% |
| Innova Captab Limited | 2.45 Billion INR | -130.217% |
| Divi's Laboratories Limited | 30 Million INR | -18709.0% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -12171.541% |
| Morepen Laboratories Limited | 289.99 Million INR | -1845.812% |
| Mankind Pharma Limited | 2.07 Billion INR | -172.367% |
| Sequent Scientific Limited | 4.87 Billion INR | -15.702% |
| Wanbury Limited | 1.16 Billion INR | -384.416% |
| Laurus Labs Limited | 25.77 Billion INR | 78.107% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 11.214% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -3190.588% |
| Alembic Limited | 91.5 Million INR | -6066.885% |
| Hikal Limited | 8.17 Billion INR | 30.983% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -9.96% |
| Neuland Laboratories Limited | 953.89 Million INR | -491.542% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -49.412% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 54.159% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -1622.436% |
| Themis Medicare Limited | 957.92 Million INR | -489.056% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 29.835% |
| Lupin Limited | 29.21 Billion INR | 80.687% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -32548.846% |
| Wockhardt Limited | 23.56 Billion INR | 76.05% |
| Vaishali Pharma Limited | 134.91 Million INR | -4082.318% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -97.816% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -6211.039% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 84.6% |
| FDC Limited | 205.18 Million INR | -2650.055% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 71.815% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -1683.041% |
| Eris Lifesciences Limited | 27.81 Billion INR | 79.712% |
| Venus Remedies Limited | 413.3 Million INR | -1265.279% |
| ZIM Laboratories Limited | 1.08 Billion INR | -418.514% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -465.174% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -28543.147% |
| Shilpa Medicare Limited | 9.37 Billion INR | 39.804% |
| Albert David Limited | 33.24 Million INR | -16874.611% |
| Ajanta Pharma Limited | 352.8 Million INR | -1499.405% |
| Hester Biosciences Limited | 2.44 Billion INR | -130.9% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -768.156% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 44.215% |
| Gufic Biosciences Limited | 3.32 Billion INR | -69.493% |
| Windlas Biotech Limited | 36.41 Million INR | -15397.665% |
| Procter & Gamble Health Limited | 95.6 Million INR | -5802.406% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -1699.772% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -472.907% |
| Granules India Limited | 13.15 Billion INR | 57.092% |
| Bal Pharma Limited | 1.39 Billion INR | -304.065% |
| Alkem Laboratories Limited | 14.18 Billion INR | 60.218% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 82.763% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -52793.701% |
| Medicamen Biotech Limited | 308.17 Million INR | -1731.023% |
| Unichem Laboratories Limited | 2.47 Billion INR | -127.975% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -2213.597% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -128464.593% |
| Valiant Laboratories Limited | 767.08 Million INR | -635.604% |
| Orchid Pharma Limited | 1.35 Billion INR | -317.419% |
| Medico Remedies Limited | 80.5 Million INR | -6909.217% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -3294.8% |
| Ipca Laboratories Limited | 14.38 Billion INR | 60.77% |
| Brooks Laboratories Limited | 56.41 Million INR | -9901.418% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -678.447% |
| Piramal Enterprises Limited | 535.85 Billion INR | 98.947% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 85.97% |
| NATCO Pharma Limited | 3.71 Billion INR | -52.012% |
| Suven Life Sciences Limited | 7.09 Million INR | -79408.243% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -191.719% |
| Strides Pharma Science Limited | 25.16 Billion INR | 77.58% |
| Indoco Remedies Limited | 6.71 Billion INR | 16.026% |
| Alpa Laboratories Limited | 52.46 Million INR | -10655.17% |
| Lasa Supergenerics Limited | 220.76 Million INR | -2456.011% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -822.764% |